Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.

Inclusion criteria

• The age of the subject was between 18 and 75 years old (inclusive), regardless of gender;
• The predicted survival time was ≥3 months;
• Newly diagnosed with NSCLC brain metastasis;
• MRI imaging showed 1-10 unresectable brain metastases;
• Karnofsky performance status (KPS) score ≥70;
• Able to operate the TTF independently or with the help of a caregiver;
• Subjects of childbearing potential had to agree to use effective contraception for the duration of the trial;
• Voluntarily signed the informed consent form.

Exclusion criteria

• Positive driver genes;
• Recurrent brain metastasis of NSCLC;
• Suffering from severe cerebral edema;
• Leptomeningeal metastases;
• Participants had to meet certain criteria for bone marrow, liver and kidney function before enrollment, and were not eligible if they had any of the following:

• platelet count < 100×103/μL;
• absolute neutrophil count < 1.5×103/μL;

d. AST or ALT exceeding 2.5 times the upper limit of normal; c.Total bilirubin more than 1.5 times the upper limit of the normal range; d.Severe renal impairment (serum creatinine >1.7 mg/dL, or >150 μmol/L);

• There were infection, ulcer and unhealed wound in the skin where the electrode was applied；
• Patients allergic to conductive hydrogels or medical adhesives;
• Those who are pregnant or preparing to become pregnant or who are breastfeeding;
• Patients with poor compliance, as judged by the investigator, or other factors considered by the investigator to be not suitable for the study.